Quantum X bio 3D bioprinter

	Next higher product group	Quantum X bioprinter (product series)
	Status	2021-12-15 sales start
	Organisation	Cellink (SE, after 8/21)
	Group	Bico (Group)
	Organisation 2	Nanoscribe GmbH & Co. KG
	Group	Bico (Group)

Bico Group AB. (12/15/21). "Press Release: Cellink and Nanoscribe Join Forces to Launch the Quantum X bio, the World’s Most Accurate 3D Bioprinter".

The Quantum X bio combines CELLINK’s bioprinting expertise with the engineering excellence of Nanoscribe to create a first-of-Its-kind bioprinter

Today, BICO companies CELLINK and Nanoscribe announced the launch of the Quantum X bio, a revolutionary printing platform providing researchers with first-of-its-kind submicron bioprinting resolution. Powered by Two Photon Polymerization (2PP), the Quantum X bio is the premier tool for miniaturizing bioprinting, redefining what it means to work within advanced biomedical applications, including tissue engineering and regenerative medicine.

Building off the revolutionary Nanoscribe Quantum X platform of printers, the Quantum X bio enables print resolution down to 100 nanometers and allows researchers to fabricate advanced microenvironments for tissue engineering, custom scaffolds for cell studies, detailed microfluidic elements and microneedle arrays or microrobots for drug delivery. With its easy-to-learn user interface and straightforward workflow, the Quantum X bio an optimal tool for researchers.

“Co-developing products like this is the exact reason why we take such pride in being a part of the BICO group,” says Cecilia Edebo, CEO of CELLINK. “We look forward to delivering this system to our customers and witnessing the marvelous breakthroughs they will achieve.”

Grounded in Nanoscribe’s engineering excellence, the proprietary technology is customized and reimagined through collaboration with the bioprinting experts at CELLINK, implementing essential features like precise temperature control, sterile environment and functionalized biomaterials. Additionally, the bioprinter unlocks a new level of resolution in bio fabrication and effectively accelerates innovation across critical applications like tissue engineering, smart hydrogel materials, drug delivery, mechanobiology and vascularized tissue.

“Our industry-proven Two-Photon Polymerization technology, combined with CELLINK’s bioprinting expertise, will be a game changer for many challenging biological and biomedical applications, and we look forward to expanding our market leading 3D Microfabrication position in the life sciences with a dedicated bioprinter," says Martin Hermatschweiler, CEO of Nanoscribe. "The launch of Quantum X bio confirms the power of collaboration within the BICO Group, and we are excited to unlock the full potential at the merger of technical and life science disciplines."

Companies and organizations interested in the Quantum X bio can find more information at cellink.com and nanoscribe.com.

BICO Press office US
Riley Munks, PR Manager: +1 (650) 863-6699
Alyssa D’Orazio, PR Manager: +1 (617) 634-9601
Email: press@bico.com

This information was submitted for publication, through the agency of the contact persons set out above, on December 15, 2021, at 9am (CET).

About BICO

Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.

The company has a focus on developing technologies that will advance Health 4.0 Next Generation Core Industry Ecosystems that enable tissue engineering, diagnostics, multiomics, and cell line development. BICO’s technologies enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.

The Group’s instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com

About CELLINK

CELLINK is creating the future of health as part of BICO, the world’s leading bio convergence company. When CELLINK released the first universal bioink in 2016, it democratized the cost of entry for researchers around the world and played a major role in turning the then up-and-coming field of 3D bioprinting into a thriving $1 billion industry. Today, the company’s best-in-class bioinks, bioprinters, software and services have been cited in over 700 publications and are trusted by more than 1,000 academic, pharmaceutical and industrial labs. At the forefront of the bioprinting industry, CELLINK aims to alleviate organ donor shortage with biofabricated transplantable organs and remains committed to reducing our dependence on animal testing and increasing efficiencies in drug development with more physiologically relevant bioprinted organ models. Visit cellink.com to learn more. BICO is listed on the Nasdaq Stockholm Main Market under BICO.

About Nanoscribe

Founded in 2007, by leading scientists and PhD Students from Karlsruhe Institute of Technology (KIT), Nanoscribe is a pioneer and the market leading company in 2PP technology. The company’s products are being used by customers in over 30 different countries worldwide, enabling customers to materialize their ground-breaking ideas. Nanoscribe has created its strong market leading position through high quality engineering and agility to continuously develop its products to meet customers’ high expectations. Nanoscribe expects to diversify its product portfolio further in the near future, to expand the customer base.

The company is headquartered near Karlsruhe, Germany, and has two subsidiaries in the US and China. Nanoscribe has around 80 employees. Read more at: www.nanoscribe.com